Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Affinergy, LLC is a for-profit organization that provides biomedical research and development services to advance diagnostic tools, particularly peptide-based assays, to support improved disease monitoring and treatment decisions. Through federal grants, the company has focused on developing rapid point-of-care tests for various indications including hepcidin monitoring, assessment of APOL1 genotype to inform kidney disease risk, and therapeutic drug monitoring.
Past federal grants awarded to Affinergy, LLC span programs across NIH Institutes and the NHLBI, NIAID, NIDDK, NIMHD, NINDS, and NIDA. As a prime recipient, Affinergy has used this funding to advance development of proprietary peptide-based assays to quantify bioactive hepcidin-25 to support iron overload disorders, a point-of-care test to rapidly determine APOL1 G0 status to inform chronic kidney disease risk and improve kidney allocation protocols, and tools for therapeutic drug monitoring including assays to measure vancomycin in hemodialysis patients and everolimus levels. Affinergy has also received grants as a subrecipient to develop multiplex assays for venous thromboembolism, cardiac sarcoidosis, chronic pain conditions, and amyotrophic lateral sclerosis. Deliverables have included optimizing the sensitivity and specificity of peptide-based assays, evaluating interference and cross-reactivity, and preparing validation packages to support regulatory filings.
Quick answers
Is Affinergy, LLC registered in SAM.gov?
Affinergy, LLC's SAM.gov registration expired on November 6, 2024.
What is Affinergy, LLC's CAGE code?
Affinergy, LLC's CAGE code is 6LEN7, and its Unique Entity ID (UEI) is YJQ6K1QMS488.
What is Affinergy, LLC's most recent federal award?
Affinergy, LLC's most recent federal grant award is Novel clinical assay to rapidly monitor posaconazole levels in plasma (R43AI155250), from National Institute of Allergy and Infectious Diseases (NIH), on January 23, 2024.
On GovTribe
See Affinergy, LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors